Story at a glance:
- Semaglutide, the blockbuster drug being used for weight loss, is slated to bring in more than $10 billion in annual sales but serious adverse effects are emerging.
- A study using data from Eudravigilance, Europe’s system for analyzing adverse reactions to medications, found a high prevalence of gastrointestinal disorders among users.
- Other semaglutide patients “experienced rapid worsening of kidney function” after use.
- Semaglutide has also been associated with cancer, pancreatitis and retinopathy complications, including hemorrhage and blindness.
- Long-term use of GLP-1RAs like semaglutide may even leave your small intestine as inelastic as a loose spring, causing a potentially fatal intestinal obstruction.
The latest weight loss craze to hit Hollywood and beyond is semaglutide, more popularly known as Ozempic, the brand name of the drug marketed to improve blood sugar in people with Type 2 diabetes.
Semaglutide is also known as Wegovy, which is prescribed to adults interested in weight loss. The weekly injectable drug is available only by prescription — and costs $1,349 a month — but it’s in high demand among those looking to shed a few pounds.
New York dermatologist Dr. Paul Jarrod Frank told People, “It’s the drug of choice these days for the 1%.”
He says he can always spot users due to “Ozempic face,” a gaunt appearance that can occur due to fat loss, which may make you appear older, particularly in the face.
But this undesirable side effect is the least of your worries if you choose to use semaglutide. The blockbuster drug, slated to bring in more than $10 billion in annual sales, has also been linked to a growing number of serious health disorders….